Alba Therapeutics Announces Positive Phase Ib Clinical Trial Results
Posted on: Monday, 13 March 2006, 09:00 CST
BALTIMORE, March 13 /PRNewswire/ -- Alba Therapeutics Corporation announced today successful completion of Phase Ib proof-of-concept studies for its lead compound, AT1001. In a 21-patient cohort of celiac disease sufferers, the oral administration of AT1001 versus placebo control induced a significantly positive result in the trial's primary target endpoint.
"We anticipated a strong signal, however, the magnitude of the response surpassed our expectations," stated Blake Paterson, M.D., President and CEO of Alba. "We are particularly excited, as to the best of our knowledge this is the first demonstration of a desired and systemic immunological effect resulting from a physiological event at a mucosal surface."
AT1001 is an antagonist to the zonulin system -- a signaling pathway discovered by Alessio Fasano, M.D., Professor of Pediatrics, Medicine and Physiology at the University of Maryland School of Medicine, and the basis of Alba's extensive intellectual property portfolio.
About Zonulin
Zonulin is a signaling protein that transiently and reversibly opens the tight junctions ("tj") between the cells of epithelial and endothelial tissues such as the intestinal mucosa, blood brain barrier and pulmonary epithelia. Zonulin appears to be involved in many diseases in which leakage occurs via paracellular transport across epithelial and endothelial tight junctions (tj), and thus may play an important potential role in the treatment of autoimmune diseases.
About Celiac Disease
Celiac disease (CD) is a T-cell mediated auto-immune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten. According to the National Institutes of Health, celiac disease affects approximately 3 million Americans, although the diagnosis is rarely made. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for some patients.
About Alba
Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to commercializing disease-modifying therapeutics and drug delivery adjuvants based on the zonulin pathway. Alba's lead molecule, AT-1001, is targeted towards the treatment of celiac disease and other auto-immune illnesses.
Contact: Heather Bakalyar, 410-522-8708 x1106
Alba Therapeutics Corporation
CONTACT: Heather Bakalyar of Alba Therapeutics Corporation,+1-410-522-8708, ext. 1106
Web site: http://www.albatherapeutics.com/
Source: PRNewswire
Related Articles
- Reportlinker Adds Autoimmune Disease Therapeutics Report
- Seventy Percent of Newly Diagnosed Alzheimer's Disease Patients Do Not Receive Treatment Within a Year of Diagnosis
- Examine Autoimmune Disease Therapeutics With This Essential Report
- Expanded Indications, Novel Targets Driving Activity in Autoimmune Disease Therapeutics
- Prefilled Syringes - Drugs, Devices and Disease Therapeutics Analyzes Eleven Important Prefilled Syringe Therapeutic Segments
- PreEmptive Meds, Inc. Leads the Way in the Pre-Disease Therapeutic Space, Providing Effective Alternatives to Physicians and Their Patients
- Autoimmune Disease Therapeutics Market to Gain From Increased Acceptance of Biologics By Physicians - European Autoimmune Diseases Therapeutics Markets
- Affordable, Innovative and Effective Solutions to Drive European Autoimmune Diseases Therapeutics Market
- Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML); Collaboration to Focus on RNAi Therapeutics Targeting the JC Virus
- Thrombotic Disease Therapeutics Market Expected To Be Worth Over USD17 Billion in 2010
 |
 |
User Comments (0)
RSS Feeds